Navigation Links
CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G

stance and the improved patient comfort due to lower PONV supports CeNeS justification of a substantial price premium for M6G compared to morphine.

We are actively pursuing potential partners for M6G and are confident that agreements can be reached. We are well positioned to deliver significant value to shareholders by the successful commercialisation of M6G".

- END -

CeNeS Pharmaceuticals plc will be announcing its preliminary results for the year ended 31 December 2006 on Wednesday 28 March 2007. On the same day the Company will be hosting an R&D presentation at the offices of Financial Dynamics. The presentation will start at 9:30am and is expected to conclude at 11am.

For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466

JM Finn Geoff Nash Tel: +44(0) 207 628 9688

Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: www.cenes.com

About M6G Morphine formulations are the gold standard treatment for the relief of moderate to severe post-operative pain. A limitation of morphine treatment is often the unpleasant side effects experienced, of which nausea and vomiting are the most common. PONV is rated among patients as one of the most distressing after-effects of surgery and reduces their quality of life.

The active potent metabolite of morphine, morphine-6-glucuronide (M6G), may offer therapeutic advantages over morphine in having an equivalent analgesic effect, but with a reduced tendency to cause nausea, vomiting and respiratory depression. Phase II and III clinical trials have sho
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
3. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:9/16/2014)... , Sept. 16, 2014  Formex, ... manufacturing, announced that Mr. Greg Weilersbacher joined Formex ... 25, 2014. Greg Weilersbacher ... experience with focused expertise in Quality Assurance, ... Mr. Weilersbacher brings to Formex a ...
(Date:9/16/2014)... , Sept. 16, 2014 On September 25 ... exhibition focusing on medical design and manufacturing - MEDTEC ... Shanghai World Expo Exhibition & Convention Center, bringing together ... and regions to showcase their latest medical-grade raw materials, ... only one week remaining for free visitor pre-registration to ...
(Date:9/16/2014)... , Sept. 16, 2014 CorMedix ... focused on developing and commercializing therapeutic products for ... infectious diseases, announces the amendment and restatement of ... preferred stock and related warrants, as well as ... stock and warrant financing, to remove anti-dilution, price ...
Breaking Medicine Technology:Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3
... Mylan Inc. (Nasdaq: MYL ) today announced ... from the U.S. Food and Drug Administration (FDA) for ... Levodopa Tablets USP, 10mg/100mg, 25mg/100mg and 25mg/250 mg. , ... Bristol Myers Squibb,s Parkinson,s treatment Sinemet®, 10mg/100mg, 25mg/100mg and ...
... JERUSALEM, Israel, September 30 Gamida Cell ... generic,name of what is widely known as "StemEx", as ... The article, carlecortemcel-l, an ex vivo expanded,umbilical cord blood ... Chan and Dr. Demetrios Petropoulos, will be published in ...
Cached Medicine Technology:Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 2Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 3
(Date:9/16/2014)... Francisco, September 15, 2014Prostate cancer patients who received ... quality of life, as well as bladder and ... after RT, according to research presented today at ... Annual Meeting. Additionally, results indicate that parallel quality ... who receive different regimens of HPFX RT. , ...
(Date:9/16/2014)... who have had children (parous women) appear to ... breast cancer, the subtype that carries a higher ... of African ancestry. A similar relationship was ... between childbearing and increased risk of estrogen receptor-negative ... the women who had never breastfed. These findings, ...
(Date:9/16/2014)... better predict a man,s risk of getting prostate cancer ... largest-ever analysis of the cancer,s genetic biomarkers, reported in ... Health and Biomedical Innovation,s Dr Jyotsna Batra and Distinguished ... the large consortia of research hubs around the world, ... markers in 80,000 men. , "It,s the largest analysis ...
(Date:9/16/2014)... Definitive Healthcare , the ... providers, is pleased to announce the release of ... now available for subscription, features detailed hospital profiles ... affiliations. , The Canadian database spans Canada’s ten ... over 750 hospitals. Each hospital profile provides ...
(Date:9/16/2014)... 16, 2014 Gary F. Locke, the ... has selected Worldwide Speakers Group for exclusive representation of ... of Commerce and Governor of Washington, Locke is widely ... U.S.-China relations, global expansion, and business growth. , “Gary ... and how to grow an organization’s global presence in ...
Breaking Medicine News(10 mins):Health News:Prostate cancer patients who receive hypofractionated RT report consistent QoL 2Health News:Prostate cancer patients who receive hypofractionated RT report consistent QoL 3Health News:Lactation linked to reduced estrogen receptor-negative, triple-negative breast cancer risk 2Health News:New gene research helps pinpoint prostate cancer risk 2Health News:Canadian Hospital Database Now Offered by Definitive Healthcare 2Health News:Gary Locke, Former Ambassador to China, Selects Worldwide Speakers Group for Exclusive Lecture Representation 2
... of Canadian surgeons got a shock when the patient they ... ,Describing the case in the Lancet, lead doctor Dr. Alana ... team was startled to discover green blood flowing in the ... 42-year-old man was being operated upon to prevent his condition-compartment ...
... able to uncover the fate of the lost colony with ... than 100 people settled on the Roanoke Island in ... and historical narratives have gathered around 168 surnames that could ... the English trying to colonize the new world. ...
... of Buffalo, for the first time in its 23 years of ... . The festival attracts tens of thousand of people from all ... vendor's menu must meet standards on fat, salt and cholesterol. ... have mango sorbet and smoked chicken sandwiches along with the hot ...
... appear healthy, making it difficult to detect outbreaks of the ... Monday. ,Indonesia, the country worst hit by ... H5N1 outbreaks across its vast archipelago. ,"From our ... bird flu have not been showing the usual symptoms," Memed ...
... Hong Kong on Monday warned the public to stop ... industrial chemical. The customs department said samples contained ... was discovered in exports of Chinese toothpaste to Panama. ... toothpaste imports and Singapore has banned three Chinese brands. ...
... body representing the vast majority of Britain's casinos ... government plans to shake-up the country's gambling ... persuade the London-based court that Labour's policy to ... Vegas-style "super-casino," was treating existing gaming establishments with ...
Cached Medicine News:Health News:DNA Link to a Lost Colony 2Health News:Healthier Options at the Buffalo Food Fest 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: